1Hassoun PM,Adnot S. Update in pulmonary vascular diseases 2011[J].American Journal of Respiratory and Critical Care Medicine,2012,(11):1177-1182.
2Simonneau G,Robbins IM,Beghetti M. Updated clinical classification of pulmonary hypertension[J].Journal of the American College of Cardiology,2009,(Suppl 1):43-54.
3Badesch DB,Champion HC,Scanchez MA. Diagnosis and assessment of pulmonary arterial hypertension[J].Journal of the American College of Cardiology,2009,(Suppl 1):55-65.
4Ivy D. Advances in pediatric pulmonary arterial hypertension[J].Current Opinion in Cardiology,2012,(02):70-81.
5Berger RM,Beghetti M,Humpl T. Clinical features of paediatric pulmonary hypertension:a registry study[J].The Lancet,2012,(9815):537-546.
6Barst R J,Ertel SI,Beghetti M. Pulmonary arterial hypertension:a comparison between children and adults[J].European Respiratory Journal,2011,(03):665-677.
7Cerro M J,Abman S,Diaz G. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease:report from the PVRI Pediatric Taskforce,Panama 2011[J].Pulm Circ,2011,(02):286-298.
9Tissot C,Ivy DD,Beghetti M. Medical therapy for pediatric pulmonary arterial hypertension[J].Journal of Pediatrics,2010,(04):528-532.
10Barst RJ,Maislin G,Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children[J].Circulation,1999,(09):1197-1208.
二级参考文献30
1Ma M, Gauvreau K, Allan CK, et al. Causes of death after congenital heart surgery. Ann Thorac Surg, 2007, 83 : 1438-1445.
2Hawort SG. The management of pulmonary hypertension in children. Arch Dis Child, 2008, 93:620-625.
3Hsu HH, Chen JS, Chen RJ, et al. Long-term outcome and effects of oral bosentan therapy in Taiwan Residents patients with advanced idiopathic pulmonary arterial hypertension. Respir Med, 2007, 101 : 1556-1562.
4Lammers AE, Hislop AA, Flynn Y, et al. The 6-minute walk test: normal values for children of 4-11 years of age. Arch Dis Child, 2008, 93:464-468.
5Keogh AM, McNeil KD, Wlodarczyk J, et al. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant, 2007, 26 : 181-187.
6Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation, 2006, 114 : 48-54.
7Barst R, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther, 2003, 73:372-382.
8Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol, 2005, 46:697-704.
9Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart, 2009, 95:312-317.
10Votava-Smith JK, Perens GS, Alejos JC. Bosentan for increased pulmonary vascular resistance in a patient with single ventricle physiology and a bidirectional Glenn shunt. Pediatr Cardiol, 2007, 28:314-316.
6Chemla D,Hervé P. Estimation of mean pulmonary artery pressure:simpler than expected[J].CHEST,2008,(03):592-593.
7Leblanc N,Ledoux J,Saleh S. Regulation of calcium-activated chloride channels in smooth muscle cells:a complex picture is emerging[J].Can J Physiol Pharmaco1,2005,(07):541-556.
8Sun H,Xia Y,Paudel O. Chronic hypoxia-induced upregulation of Ca2 +-activated C1-channel in pulmonary arterial myocytes:a mechanism contributing to enhanced vasoreactivity[J].JOURNAL OF PHYSIOLOGY,2012,(15):3507-3521.
9Tajsic T,Morrell NW. Smooth muscle cell hypertrophy,proliferation,migration and apoptosis in pulmonary hypertension[J].Compr Physiol,2011,(01):295-317.
10Soon E,Holmes AM,Treacy CM. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension[J].CIRCULATION,2010,(09):920-927.
